The role of apoB measurement in Type 2 diabetic patients

Q Medicine

Clinical Lipidology Pub Date : 2015-04-01 DOI:10.2217/clp.15.6

Brian Lee, Busadee Pratumvinit, N. Thongtang

引用次数: 3

Abstract

Abstract Aims: ApoB and non-HDL-C more accurately quantify cardiovascular risk than LDL-C; however, controversies exist over which is more clinically useful. We determined how well non-HDL-C targets predicted the attainment of apoB goals. Materials & Methods: In this cross-sectional study of Type 2 diabetic patients who achieved LDL-C <100 mg/dl, apoB and non-HDL-C concentrations, and the accuracy of non-HDL-C targets against apoB goals were determined. Results: Positive predictive values of non-HDL-C goals in predicting attainment of apoB goals were 90.3%, but were reduced in patients with hypertriglyceridemia or coronary heart disease (CHD). Conclusion: ApoB measurement could be useful in evaluating cardiovascular risk in diabetic subjects with hypertriglyceridemia or CHD who have already achieved LDL-C and non-HDL-C targets.

查看原文本刊更多论文

载脂蛋白ob测定在2型糖尿病患者中的作用

目的:ApoB和非hdl - c比LDL-C更准确地量化心血管风险;然而，关于哪一种在临床上更有用存在争议。我们确定了非hdl - c指标对apoB目标实现的预测程度。材料与方法:对LDL-C <100 mg/dl的2型糖尿病患者进行横断面研究，确定载脂蛋白ob和非hdl - c浓度，并确定非hdl - c靶对载脂蛋白ob靶的准确性。结果:非hdl - c目标预测载脂蛋白目标实现的阳性预测值为90.3%，但在高甘油三酯血症或冠心病(CHD)患者中，阳性预测值降低。结论:载脂蛋白ob检测可用于评估已达到LDL-C和非hdl - c目标的伴有高甘油三酯血症或冠心病的糖尿病患者的心血管风险。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Lipidology 生物-生化与分子生物学

CiteScore

0.44

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： The Journal of Clinical Lipidology is published to support the diverse array of medical professionals who work to reduce the incidence of morbidity and mortality from dyslipidemia and associated disorders of lipid metabolism. The Journal''s readership encompasses a broad cross-section of the medical community, including cardiologists, endocrinologists, and primary care physicians, as well as those involved in the treatment of such disorders as diabetes, hypertension, and obesity. The Journal also addresses allied health professionals who treat the patient base described above, such as pharmacists, nurse practitioners and dietitians. Because the scope of clinical lipidology is broad, the topics addressed by the Journal are equally diverse. Typical articles explore lipidology as it is practiced in the treatment setting, recent developments in pharmacological research, reports of treatment and trials, case studies, the impact of lifestyle modification, and similar academic material of interest to the practitioner. While preference is given to material of immediate practical concern, the science that underpins lipidology is forwarded by expert contributors so that evidence-based approaches to reducing cardiovascular and coronary heart disease can be made immediately available to our readers. Sections of the Journal will address pioneering studies and the clinicians who conduct them, case studies, ethical standards and conduct, professional guidance such as ATP and NCEP, editorial commentary, letters from readers, National Lipid Association (NLA) news and upcoming event information, as well as abstracts from the NLA annual scientific sessions and the scientific forums held by its chapters, when appropriate.